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SUMMARY – Infl ammation plays an important role in the initiation and progression of periph-
eral artery disease (PAD). Patients with diabetes have an increased risk of developing PAD. Data 
 regarding the prognostic implication of diabetes and infl ammation in PAD patients are scarce. Th e 
aim of the study was to investigate the impact of diabetes and infl ammation on all-cause mortality in 
patients with symptomatic PAD and preserved left ventricular ejection fraction (LVEF >50%). Th e 
study was conducted at the Sestre milosrdnice University Hospital Center between January 2010 and 
January 2014 on 319 consecutive patients with symptomatic PAD and preserved LVEF (66.5% men, 
mean age 70±10 years, ankle brachial index 0.58±0.14). Th irty-eight (12%) patients died during 
 median follow up period of 24 months (interquartile range, 16-34 months). On univariate analysis, 
C-reactive protein was signifi cantly associated with all-cause mortality (HR 2.21, 95% CI 1.09-4.48). 
After multivariate regression analysis, age (HR 1.07, 95% CI 1.02-1.11), diabetes (HR 2.24, 95% CI 
1.04-4.82), and critical limb ischemia (HR 2.22, 95% CI 1.03-4.80) remained the only independent 
predictors for all-cause mortality. Diabetes and critical limb ischemia are independently associated 
with an increased risk of mortality in symptomatic PAD patients with preserved LVEF.
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Introduction
Peripheral artery disease (PAD) is a multifactorial 
syndrome that is associated with a very high risk of 
ischemic events, namely myocardial infarction, stroke, 
and death1. Th e probability of having polyvascular dis-
ease is greater in patients with PAD, indicating an ex-
tensive and severe degree of systemic atherosclerosis. 
Th ese patients, despite more intense medical therapy, 
have poorer control of modifi able risk factors and 
higher mortality rate2,3.
Patients with diabetes mellitus have a 2- to 4-fold 
higher risk of developing PAD4,5. Progression of ath-
erosclerosis, as well as poor outcomes, are more often 
present in diabetic PAD patients, probably because of 
the abnormal metabolic state and increase in vascular 
infl ammation6. PAD has been identifi ed as a risk fac-
tor for glycemic dysregulation in type 2 diabetes mel-
litus7. Prospective clinical trials have shown that the 
occurrence of major adverse cardiovascular events 
(MACE) and all-cause mortality is higher in patients 
with both diabetes and PAD than in nondiabetic PAD 
patients8-10.
C-reactive protein (CRP) has been established as a 
risk factor for the development of type 2 diabetes and 
cardiovascular disease, including PAD11,12. Elevated 
CRP levels are present in patients with impaired glu-
cose tolerance and are associated with the stage of be-
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ta-cell dysfunction and insulin resistance13. Results 
from the West of Scotland Coronary Prevention Study 
have shown that CRP concentration is a signifi cant 
predictor of diabetes in middle-aged men, indepen-
dent of the risk factors such as body mass index, fast-
ing triglycerides and glucose levels14. Th e predictive 
role of CRP has been well studied in acute coronary 
and acute aortic syndromes15,16. We have recently 
shown that CRP independently predicted MACE in 
patients with symptomatic PAD and preserved left 
ventricular systolic function17. Patients with PAD have 
a higher prevalence of diabetes and higher levels of in-
fl ammatory biomarkers compared to patients without 
PAD18.
Th erefore, the aim of the study was to investigate 
the role of diabetes and infl ammation for all-cause 
mortality in patients with symptomatic PAD and nor-
mal left ventricular ejection fraction (LVEF).
Patients and Methods
Th e study population consisted of 319 consecutive 
patients with symptomatic PAD and preserved LVEF 
admitted to the Sestre milosrdnice University Hospital 
Center between January 2010 and January 2014. Fifty-
fi ve patients were excluded due to LVEF <50% (n=39), 
malignancy (n=12) and concomitant autoimmune dis-
orders (n=4). During hospital stay, demographic data 
and clinical characteristics of the patients were recorded 
and included general information (age, sex, weight and 
height), data on cardiovascular risk factors, biochemical 
and hematological laboratory data, comorbidities, and 
medications. Renal function was assessed by estimating 
the glomerular fi ltration rate (eGFR) using the Modifi -
cation of Diet in Renal Disease formula19. LVEF was 
assessed using transthoracic echocardiography (Simp-
son’s method), and only patients with preserved LV sys-
tolic function (LVEF >50%) were included in the study. 
Baseline anemia was defi ned according to the World 
Health Organization criteria (hemoglobin level <13 g/
dL for men and <12 g/dL for women)20.
Th e diagnosis of PAD was established by clinical 
examination, ankle brachial index (ABI) measurement, 
duplex sonography and/or computed tomography or 
magnetic resonance angiography, and confi rmed with 
peripheral angiography using the criteria of the Euro-
pean Society of Cardiology and American College of 
Cardiology Foundation21,22. According to the Fontaine 
classifi cation, among symptomatic PAD patients with 
preserved LVEF there were 58% of patients in stage 
IIB, 24% of patients in stage III and 18% of patients in 
stage IV. Critical limb ischemia (CLI) was defi ned as 
the presence of rest pain, ulcer or gangrene (Fontaine 
stages III and IV)21.
Diabetes was defi ned according to the criteria of 
the American Diabetes Association and was consid-
ered to be present in all patients taking antidiabetic 
medication23.
Hypertension was diagnosed in accordance with 
the European Society of Cardiology/European Soci-
ety of Hypertension 2013 guidelines24.
Cardiovascular disease, in addition to confi rmed 
PAD, was defi ned as history of angina, myocardial in-
farction, coronary revascularization (percutaneous 
coronary intervention or coronary artery bypass graft-
ing), history of stroke, transient ischemic attack, or ca-
rotid revascularization.
High sensitivity CRP was determined on admis-
sion by immunoturbidimetric method (Olympus, 
Dublin, Ireland).
Study endpoint was the all-cause mortality. Mor-
tality was documented by death certifi cates or by re-
viewing hospital records. Th e median follow up was 24 
months (interquartile range 16-34 months). Outcome 
was assessed by independent observers blinded to pa-
tient laboratory and clinical data. Th e investigation 
was performed in accordance with the Declaration of 
Helsinki and was approved by the University Hospital 
Center Ethics Committee.
Continuous normally distributed variables were ex-
pressed as mean (± standard deviation) and non-nor-
mally distributed variables as medians (interquartile 
range). Diff erences between the groups were analyzed 
with t-test and Mann-Whitney test for continuous 
variables and with c2-test for categorical variables. Nor-
mality of distribution was tested with Kolmogorov-
Smirnov test. Th e ability of CRP to predict mortality 
was tested by the receiver-operating characteristic 
(ROC) analysis and optimal cut-off  point of CRP was 
dichotomized to > or <4.5 mg/L. Kaplan-Meier analy-
ses with log-rank test were performed and comparisons 
were based on the presence of diabetes and CLI. Cox 
proportional-hazards regression analysis was performed 
to determine the independent predictors of all-cause 
mortality and results were expressed as hazard ratios 
(HR) and 95% confi dence intervals (CI). Covariate se-
lection included known correlates of poor cardiovascu-
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lar outcome and those that were found to be signifi cant 
on univariate analysis, i.e. age, gender, CLI, anemia, re-
nal function, CRP and diabetes. Th e value of p<0.05 was 
considered statistically signifi cant. Statistical analysis 
was performed using the MedCalc® Version 11.3.1.0 
(MedCalc, Ostend, Belgium).
Results
Baseline characteristics of the study population are 
shown in Table 1. Of 319 symptomatic PAD patients 
with preserved LVEF, 172 (54%) had type 2 diabetes. 
Table 1. Baseline characteristics of 319 patients with 
symptomatic peripheral artery disease and preserved left 
ventricular systolic function
Characteristic
Age (years)* 71 (63-78)
Male sex, n (%) 212 (66.5)
Ankle brachial index † 0.58±0.14
Systolic blood pressure (mm Hg)* 140 (130-154)
Diastolic blood pressure (mm Hg)* 80 (80-90)
Heart rate (beat/min)* 75 (67-80)
Body mass index (kg/m2)* 27 (25-30)
Hypertension, n (%) 277 (87)
Diabetes mellitus, n (%) 172 (54)
Smoking, n (%) 173 (54)
Dyslipidemia, n (%) 242 (76)
Polyvascular disease, n (%) 132 (41)
Critical limb ischemia, n (%) 134 (42)
Anemia, n (%) 67 (21)
High sensitivity C-reactive protein 
(mg/L)*
4.5 (2.2-10.0)
Estimated glomerular fi ltration rate 
(mL/min)†
63.4±18.3
Left ventricular ejection 
fraction (%) †
57.0±5.5
Statin therapy, n (%) 194 (61)
Antiplatelet therapy, n (%) 299 (94)
*Median (interquartile range); †mean ± standard deviation
Fig. 1. Cumulative survival according to the presence of: 
(A) critical limb ischemia (CLI); (B) diabetes mellitus 
(DM); and (C) combined eff ect of diabetes and CLI in 
319 patients with symptomatic peripheral artery disease 
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Among diabetics, 149 (87%) were on oral hypoglyce-
mic therapy or insulin, and 23 (13%) were on diet. 
Th irty-eight (12%) patients died during median follow 
up period of 24 months (interquartile range 16 to 34 
months). On univariate analysis, age (p<0.001), CLI 
(p<0.001), diabetes (p=0.025), anemia (p<0.001), renal 
impairment (p=0.073) and CRP (p=0.029) were sig-
nifi cantly associated with all-cause mortality (Table 2). 
CLI and diabetes predicted freedom from all-cause 
mortality, and patients having both CLI and diabetes 
were 6.6 times (95% CI 2.89-14.99) more likely to die 
than those with claudication but without diabetes 
(Fig. 1A, 1B, and 1C). After multivariable analysis, 
age, diabetes and CLI remained the only independent 
predictors of mortality (Table 2).
Discussion
Th e present study investigated the prognostic role 
of diabetes and infl ammation for all-cause mortality in 
patients with symptomatic PAD and preserved LVEF. 
Age, diabetes, and CLI were found to be the only in-
dependent predictors of all-cause mortality in the 
study population.
Previous epidemiological studies showed a higher 
incidence of PAD in diabetic patients. Furthermore, 
patients with both PAD and diabetes have more often 
CLI, a higher prevalence of amputation and greater 
risk of mortality25. Our study showed the patients with 
symptomatic PAD and diabetes to be at more than 
twofold greater risk of death compared with non-dia-
betic PAD patients. Th is is in line with Leibson et al.26, 
who showed that the adjusted risk of all-cause mortal-
ity in patients with both PAD and diabetes was 2.2 
times higher than for patients with PAD alone. 
Golledge et al.27 investigated patients with occlusive or 
aneurysmal disease of peripheral arteries and showed 
1.6- to 1.7-fold and 2.0- to 2.9-fold higher mortality 
risk in patients with non-medicated diabetes and pa-
tients with diabetes receiving insulin, respectively, as 
compared with non-diabetics.
Critical limb ischemia is the most severe form of 
PAD with poor overall survival. Th e annual mortality 
rate in patients with CLI is approximately 25% and 
between 50% and 70% at 5 years28. Lower ABI values 
and diabetes are the most important risk factors for 
the development of CLI29. Vogt et al.30 have reported 
that patients with ABI <0.5 have a higher relative risk 
of all-cause mortality compared to patients with high-
er ABI values. In our study, patients with CLI had two 
times increased risk of all-cause mortality compared to 
patients without CLI.
C-reactive protein is a regularly used biomarker in 
daily clinical practice, and of note, patients with diabe-
tes have increased levels of infl ammatory biomarkers, 
such as CRP8. Data on the prognostic role of CRP for 
all-cause mortality in PAD patients are controversial. 
It has been shown that in patients with symptomatic 
PAD, increased CRP values are independently associ-
ated with all-cause mortality within 2 years, but at lon-
ger follow up period, the biomarker lost its prognostic 
signifi cance31. CRP is associated with the development 
and severity of PAD, as well as of impaired glucose 
regulation12. Moreover, in patients with PAD, elevated 
Table 2. Univariate and multivariate Cox proportional-hazards regression analysis for all-cause mortality
Univariate Multivariate
Variable HR (95% CI) p-value HR (95% CI) p-value
Age 1.081 (1.038-1.125) <0.001 1.066 (1.021-1.113) 0.004
Female sex 1.404 (0.738-2.671) 0.304 -
Hypertension 2.685 (0.650-11.081) 0.174 -
Diabetes mellitus 2.295 (1.116-4.718) 0.025 2.241 (1.041-4.824) 0.040
Critical limb ischemia 3.592 (1.695-7.611) <0.001 2.220 (1.026-4.803) 0.044
Polyvascular disease 1.667 (0.884-3.142) 0.116 -
hsCRP (>4.5 mg/L) 2.206 (1.088-4.475) 0.029 -
eGFR (<60 mL/min) 1.806 (0.951-3.430) 0.073 -
Anemia 3.724 (1.976-7.016) <0.001 1.897 (0.952-3.780) 0.070
HR = hazard ratio; CI = confi dence interval; hsCRP = high sensitivity C-reactive protein; eGFR = estimated glomerular fi ltration rate
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CRP levels correlate with the risk of cardiovascular 
mortality32. Recently, Mueller et al.33 have reported 
that CRP and CLI were independent predictors of 
death among patients with symptomatic PAD. Our 
study clearly revealed that CRP was signifi cantly as-
sociated with all-cause mortality on the univariate but 
not after multivariate analysis.
Although anemia was found to be an independent 
predictor of composite outcome (death and limb am-
putation) in patients hospitalized for PAD, it was not 
included in the earlier outcome studies34.
We have to bear in mind that patients with chronic 
kidney disease have an increased risk of developing PAD, 
and renal impairment was found to predict all-cause 
mortality in patients with symptomatic PAD35,36. Left 
ventricular systolic dysfunction is quite prevalent in PAD 
patients and is associated with all-cause mortality37.
So, we believe this is the fi rst report that showed 
the independent prognostic role of diabetes and CLI 
for mortality in symptomatic PAD patients with pre-
served left ventricular systolic function, regardless of 
renal function, anemia and infl ammation.
Patients with PAD are at an increased risk of 
MACE and all-cause mortality compared to general 
population. Additionally, lower ABI values correlated 
with reduced survival and increased rate of concomi-
tant coronary and cerebrovascular disease38. Despite a 
very high incidence of MACE and mortality rate, 
PAD is still underdiagnosed and undertreated. Th ere-
fore, screening for PAD, early management, together 
with modifi cation of cardiovascular risk factors and 
timely assessment of prognosticators for unfavorable 
outcome are of utmost importance.
In conclusion, our data confi rm that diabetes and 
CLI are independent predictors for all-cause mortality 
in patients with symptomatic PAD and preserved LVEF. 
Additionally, the coexistence of CLI and diabetes sig-
nifi cantly increased the risk of worse clinical outcome.
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Sažetak
ŠEĆERNA BOLEST I KRITIČNA ISHEMIJA EKSTREMITETA: SMRTONOSNI DVOJAC 
U BOLESNIKA SA SIMPTOMATSKOM PERIFERNOM ARTERIJSKOM BOLEŠĆU
M. Vrsalović i K. Vučur
Upala igra važnu ulogu u nastanku i napredovanju periferne arterijske bolesti (PAB). Bolesnici sa šećernom bolešću  imaju 
povišen rizik za razvoj PAB. Podatci o utjecaju šećerne bolesti i upale na prognozu PAB su oskudni. Cilj studije bio je istra-
žiti utjecaj šećerne bolesti i upale na ukupnu smrtnost u bolesnika sa simptomatskom PAB i očuvanom sistoličkom funkci-
jom lijeve klijetke (istisna frakcija lijeve klijetke >50%). Studija je provedena u razdoblju od siječnja 2010. do siječnja 2014. 
godine na 319 bolesnika sa simptomatskom PAB i očuvanom sistoličkom funkcijom lijeve klijetke (66,5% muškaraca, pro-
sječna dob 70±10 godina, pedobrahijalni indeks 0,58±0,14). Tijekom razdoblja praćenja od 24 mjeseca (interkvartilni raspon 
16-34 mjeseca) 38 (12%) bolesnika je umrlo. C-reaktivni protein bio je statistički značajno povezan s ukupnom smrtnošću u 
univarijatnoj analizi (HR 2,21; 95% CI 1,09-4,48). Nakon multivarijatne regresijske analize, dob (HR 1,07; 95% CI 1,02-
1,11), šećerna bolest (HR 2,24; 95% CI 1,04-4,82) i kritična ishemija ekstremiteta (HR 2,22; 95% CI 1,03-4,80) bile su 
jedini značajni nezavisni predskazatelji ukupne smrtnosti. Šećerna bolest i kritična ishemija ekstremiteta nezavisno su pove-
zani s povišenim rizikom smrtnosti u bolesnika sa simptomatskom PAB i očuvanom sistoličkom funkcijom lijeve klijetke.
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